City Therapeutics Stock: Growth
CTYCity Therapeutics reported $8.16B in revenue for fiscal 2019, down 4% on the prior year, down 1.6% a year on average over up to five years. That makes four years of decline in a row.
Daily figure as of 20 Nov 2026
Growth per Year by Period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2014 | since 2009 | since 2005 | |
|---|---|---|---|
| Revenue | −1.6% | −1.7% | −1.5% |
| Revenue per share | no data | no data | no data |
| Earnings | 13.5% | 4.3% | 4.6% |
| Earnings per share | no data | no data | no data |
| Free cash flow | 6.8% | 1.0% | 0.3% |
| Free cash flow per share | no data | no data | no data |
Growth Over Time
Revenue is 12% below its high of $9.27B in 2010. City Therapeutics has made a profit in every fiscal year since 2005. In the quarter to 30 Jun 2020 revenue fell 74.5% on the prior year quarter, after an average of minus 4.7% in the four quarters before.
Fiscal Years at a Glance
How Revenue and Earnings Grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2005 | $10.05B | $977M | $2.18B |
| 2006 | $9.87B | $1.2B | $1.95B |
| 2007 | $9.88B | $1.49B | $2.22B |
| 2008 | $10.39B | $1.44B | $2.08B |
| 2009 | $9.73B | $1.2B | $2.06B |
| 2010 | $9.27B | $1.08B | $2B |
| 2011 | $6.64B | $543M | $1.17B |
| 2012 | $8.85B | $849M | $1.51B |
| 2013 | $8.75B | $964M | $1.45B |
| 2014 | $8.84B | $970M | $1.64B |
| 2015 | $8.96B | $1.07B | $1.34B |
| 2016 | $8.91B | $1.09B | $1.39B |
| 2017 | $8.55B | $1.66B | $1.11B |
| 2018 | $8.49B | $1.67B | $2.75B |
| 2019 | $8.16B | $1.83B | $2.28B |
Revenue by Segment
How City Therapeutics Inc. makes its money and how that has shifted. Names are as the company reports them.
- Legacy Services$3.5B39%
- Strategic Services$3.3B37%
- Affiliates and Other Services$2.1B24%
The company split earlier years differently. A history would not be comparable, so only 2012 is shown.
Figures as a table
| 2012 | Share 2012 | |
|---|---|---|
| Legacy Services | $3.47B | 39.2% |
| Strategic Services | $3.27B | 36.9% |
| Affiliates and Other Services | $2.11B | 23.9% |
| Total revenue | $8.85B | 100% |
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026
- Price: closing price of 19 Nov 2026
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2019. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
